Sipuleucel-T, sold under the brand name Provenge, developed by Dendreon Pharmaceuticals, LLC, is a cell-based cancer immunotherapy for prostate cancer...
16 KB (1,405 words) - 17:07, 25 November 2023
Cancer immunotherapy (redirect from Adoptive T-cell therapy)
Currently, only one vaccine (sipuleucel-T for prostate cancer) has been approved. In cell-mediated therapies like CAR-T cell therapy, immune cells are...
89 KB (10,338 words) - 14:21, 16 July 2024
Immunotherapy (redirect from Regulatory T cell therapy)
the production team that produced Sipuleucel-T developed by Dendreon and the Immune Response Corporation. Whether T cells are genetically engineered or...
59 KB (6,128 words) - 05:06, 8 July 2024
after the vaccine is delivered. The best known dendritic cell vaccine is Sipuleucel-T (Provenge), which only improved survival by four months. The efficacy...
27 KB (3,139 words) - 16:25, 16 August 2024
hypertension, diabetes, cancer, or autoimmune disease.[citation needed] Sipuleucel-T is the first DCs- based cancer vaccine for men with asymptomatic or minimally...
14 KB (1,614 words) - 18:48, 17 July 2024
approved by USA Food and Drug Administration, as following; Provenge is Sipuleucel-T, a dendritic cell based vaccine for prostate cancer. Bacillus Calmettle-Guerin...
8 KB (1,116 words) - 15:42, 21 June 2024
biotechnology company. Its lead product, Provenge (known generically as sipuleucel-T), is an immunotherapy for prostate cancer. It consists of a mixture of...
15 KB (1,593 words) - 01:26, 15 August 2024
topotecan for chemotherapy of cancer 2010 – US FDA approves immunotherapy, sipuleucel-T dendritic cell vaccine for advanced prostate cancer 2010 – China advances...
27 KB (2,580 words) - 18:15, 7 September 2023
inhibitor abiraterone acetate. An alternative is the cell therapy procedure Sipuleucel-T, where the affected person's immune cells are removed, treated to more...
76 KB (8,857 words) - 09:52, 1 September 2024
L03AX15 Mifamurtide L03AX16 Plerixafor L03AX17 Sipuleucel-T L03AX18 Cridanimod L03AX19 Dasiprotimut-T L03AX21 Elapegademase L03AX22 Leniolisib QL03AX90...
2 KB (353 words) - 05:13, 18 December 2023
that invention, Sipuleucel-T, more commonly known as Provenge, became the first FDA-approved immunotherapeutic cancer vaccine. Sipuleucel-T, initially approved...
15 KB (1,741 words) - 20:59, 3 August 2024
of cancer treatment research include: Anti-cancer vaccines Oncophage Sipuleucel-T (Provenge) is a prostate cancer vaccine Inactivated tumor cells are investigated...
46 KB (5,981 words) - 21:05, 15 July 2024
number of tumors, notably malignant melanoma and renal cell carcinoma. Sipuleucel-T is a vaccine-like strategy for prostate cancer in which dendritic cells...
70 KB (8,437 words) - 00:43, 5 August 2024
sipatrigine (INN) siplizumab (INN) sipoglitazar (USAN) siponimod (INN) sipuleucel-T (USAN) siratiazem (INN) sirolimus (INN) sirukumab (INN) sisomicin (INN)...
4 KB (264 words) - 05:09, 18 July 2024
also served as the lead investigator for Dendreon's clinical trials for Sipuleucel-T, a therapeutic vaccine for prostate cancer approved in 2010. After 28...
10 KB (968 words) - 17:06, 7 November 2023
O, Salama A. Kantoff P.W., Higano C.S., Shore N.D.; et al. (2010). "Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer". N Engl J Med...
6 KB (637 words) - 17:20, 20 November 2023
Men with Metastatic Androgen Independent Prostate Cancer to Evaluate Sipuleucel-T Manufactured with Different Concentrations of PA2024 Antigen (P07-2)...
12 KB (1,179 words) - 10:16, 7 April 2024
PMC 10355925. PMID 26024831. S2CID 10625154. Slovin SF (29 September 2015). "Sipuleucel-T - A Model for Immunotherapy Trial Development". In Mydlo JH, Godec CJ...
99 KB (10,979 words) - 17:57, 1 September 2024
Neuvenge (redirect from Lapuleucel-T)
Responses for the 2010 PLI at Dendreon's Manufacturing Facility for Sipuleucel-T at Morris Plains, New Jersey - Provenge". U.S. Food and Drug Administration...
10 KB (1,114 words) - 06:32, 29 April 2024
Evaluate Sipuleucel-T Manufactured with Different Concentrations of PA2024 Antigen (P07-2). GCO 09–1509. An open label study of sipuleucel-T in men with...
22 KB (2,336 words) - 02:40, 16 January 2023
pp. 432. ISBN 9780199334414. immune response corporation kimberlin. "Sipuleucel-T: APC 8015, APC-8015, prostate cancer vaccine". Drugs in R&D. 7 (3): 197–201...
10 KB (1,011 words) - 18:51, 3 November 2023
released or are undergoing clinical trial. FDA-approved vaccines, such as Sipuleucel-T for metastasizing prostate cancer or Nivolumab for melanoma and lung...
45 KB (4,771 words) - 05:51, 2 September 2024
(abiraterone) - FDA Approved Xgeva (denosumab) - FDA Approved Provenge (sipuleucel-T) - FDA Approved Xofigo (Radium-223 dichloride) – FDA Approved supported...
21 KB (2,471 words) - 09:27, 7 December 2023
in April 2009 and is supported by Cougar Biotechnology. A Registry of Sipuleucel-T Therapy in men with advanced prostate Cancer. The study began in June...
26 KB (2,617 words) - 19:06, 2 June 2024